Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Xilio Therapeutics, Inc.
A biotechnology company in Waltham, Massachusetts, that designs cancer treatments meant to switch on only inside a tumor, so the body's own immune system attacks the cancer while healthy tissue is left alone. Its pipeline includes tumor-activated proteins like an IL-12 therapy, built on a masking platform the company calls GPS. Founded in 2016 as Akrevia Therapeutics and renamed Xilio in 2020, the name comes from the Latin phrase "ex nihilo," meaning "out of nothing," nodding to the idea of creating a new kind of cancer medicine.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
3.03 Material Modification to Rights of Security Holders · 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders